glp-1 drugs trulicity ADA: Lilly's tops Ozempic at keeping patients compliant, real-world data show Weight loss drugs don't work

P = 0.0006 for superiority) [60]

Available from: Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al

As I have been predicting, the gross-to-net bubble is deflating due to the combined impacts of government actions and consumer behavior

The emergence of tri-agonists, combining GLP-1R/GIPR and glucagon (GCG) receptor (GCGR) agonists (GLP-1R/GIPR/GCGR agonist), has also shown promising results by leading to more significant weight loss, a greater percentage of individuals attaining weight loss, further lowering lipid levels, improving T2DM management, and enhancing overall substrate metabolism compared to the use of GLP-1R agonists alone (Lyons & Beaudry 2023)

10.1016/j.cmet.2016.12.009 57 HuntingtonG